Dietary Management, Clinical Status and Outcome of Patients with Citrin Deficiency in the UK.
Adolescent
Adult
Biomarkers
/ blood
Child
Child, Preschool
Citrullinemia
/ blood
Diet, High-Fat
/ methods
Diet, High-Protein Low-Carbohydrate
/ methods
Dietary Supplements
Female
Health Status
Humans
Infant
Longitudinal Studies
Male
Phenotype
Retrospective Studies
Treatment Outcome
Triglycerides
/ administration & dosage
United Kingdom
Young Adult
FTTDCD
NICCD
citrin deficiency
clinical status
dietary management
outcomes
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
29 Oct 2020
29 Oct 2020
Historique:
received:
22
09
2020
revised:
22
10
2020
accepted:
26
10
2020
entrez:
3
11
2020
pubmed:
4
11
2020
medline:
15
4
2021
Statut:
epublish
Résumé
Little is known about the optimal dietary treatment for citrin deficiency. Our aim is to describe the management of UK citrin deficiency patients. A longitudinal retrospective review was performed. Data were collected from medical records on presenting signs and symptoms, dietary management and clinical outcome. data were collected on 32 patients from 21 families. 50% were females (16/32). Median age at diagnosis was 4 y (5 days-35 y) with 12 patients diagnosed in the neonatal period with neonatal intrahepatic cholestasis (NICCD), eight later in childhood (FTTDCD) and 12 by family screening based on index cases from five families. No patient had adult-onset type II citrullinemia. The patient age at the time of data collection was a median of 11 y (1-44 y). 91% (29/32) of patients had normal physical and neurological development, 47% (15/32) experienced recurrent unexplained abdominal pain and 9% (3/32) episodes of hypoglycaemia. Siblings had different phenotypes (5 families had > 1 affected patient). Most patients preferred high protein foods, limiting sugar-containing foods. Only 41% (13/32) were prescribed a low CHO, high protein, high fat diet (restriction varied) and two used medium chain triglyceride (MCT) supplements. No patient was prescribed drug therapy. Twenty-five per cent (8/32) of patients were underweight and 41% (13/32) had height <-1 z-scores. patients presented with various phenotypes, symptoms and suboptimal growth. Symptoms and biochemical markers improved with age, but height remained low in some. More research is necessary to assess the effectiveness of dietary approaches in improving clinical outcomes and symptoms in citrin deficiency.
Sections du résumé
BACKGROUND
BACKGROUND
Little is known about the optimal dietary treatment for citrin deficiency. Our aim is to describe the management of UK citrin deficiency patients.
METHODS
METHODS
A longitudinal retrospective review was performed. Data were collected from medical records on presenting signs and symptoms, dietary management and clinical outcome.
RESULTS
RESULTS
data were collected on 32 patients from 21 families. 50% were females (16/32). Median age at diagnosis was 4 y (5 days-35 y) with 12 patients diagnosed in the neonatal period with neonatal intrahepatic cholestasis (NICCD), eight later in childhood (FTTDCD) and 12 by family screening based on index cases from five families. No patient had adult-onset type II citrullinemia. The patient age at the time of data collection was a median of 11 y (1-44 y). 91% (29/32) of patients had normal physical and neurological development, 47% (15/32) experienced recurrent unexplained abdominal pain and 9% (3/32) episodes of hypoglycaemia. Siblings had different phenotypes (5 families had > 1 affected patient). Most patients preferred high protein foods, limiting sugar-containing foods. Only 41% (13/32) were prescribed a low CHO, high protein, high fat diet (restriction varied) and two used medium chain triglyceride (MCT) supplements. No patient was prescribed drug therapy. Twenty-five per cent (8/32) of patients were underweight and 41% (13/32) had height <-1 z-scores.
CONCLUSIONS
CONCLUSIONS
patients presented with various phenotypes, symptoms and suboptimal growth. Symptoms and biochemical markers improved with age, but height remained low in some. More research is necessary to assess the effectiveness of dietary approaches in improving clinical outcomes and symptoms in citrin deficiency.
Identifiants
pubmed: 33137944
pii: nu12113313
doi: 10.3390/nu12113313
pmc: PMC7693899
pii:
doi:
Substances chimiques
Biomarkers
0
Triglycerides
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : undefined <span style="color:gray;font-size:10px;">undefined</span>
ID : British Inherited Metabolic Disorders Group summer studentship grant
Références
J Inherit Metab Dis. 2018 Sep;41(5):777-784
pubmed: 29651749
JIMD Rep. 2012;2:37-44
pubmed: 23430852
J Inherit Metab Dis. 2020 Aug 1;:
pubmed: 32740958
Clin J Gastroenterol. 2020 Oct;13(5):823-833
pubmed: 31898207
Mol Genet Metab. 2010;100 Suppl 1:S59-64
pubmed: 20233664
J Inherit Metab Dis. 2008 Jun;31(3):386-94
pubmed: 18415701
Mol Genet Metab. 2019 Jul;127(3):175-183
pubmed: 31255436
Biochim Biophys Acta. 1999 Sep 20;1455(1):1-11
pubmed: 10524224
Bull World Health Organ. 2007 Sep;85(9):660-7
pubmed: 18026621
Intern Med. 2005 Mar;44(3):188-95
pubmed: 15805705
Intern Med. 2010;49(3):243-7
pubmed: 20118603
J Pediatr. 1975 Nov;87(5):731-8
pubmed: 1185337
Tohoku J Exp Med. 2016;240(4):323-328
pubmed: 28003588
J Inherit Metab Dis. 2019 May;42(3):501-508
pubmed: 30715743
Nat Genet. 1999 Jun;22(2):159-63
pubmed: 10369257
Hepatol Res. 2003 May;26(1):68-72
pubmed: 12787807
Mol Genet Metab. 2013 May;109(1):9-13
pubmed: 23453692
Lancet. 2012 Sep 1;380(9844):824-34
pubmed: 22770478
Am J Public Health. 1996 Apr;86(4):544-50
pubmed: 8604787
Acta Paediatr Suppl. 2006 Apr;450:76-85
pubmed: 16817681
Pediatrics. 2007 Mar;119(3):e773-7
pubmed: 17332192
Sci Rep. 2019 Mar 12;9(1):4179
pubmed: 30862943
Eur J Pediatr. 2002 Nov;161(11):609-13
pubmed: 12424587